CB Therapeutics GTM brain
CB Therapeutics uses engineered yeast, fermentation and AI-assisted design to develop natural and novel molecules for health research and product partners.
category
Synthetic biology and therapeutic molecule developmentmarket profile
- text: The platform combines microbial production of scarce natural compounds with AI-assisted design and laboratory screening of new therapeutic candidates.
- text: Potential applications include longevity research, mental health research and compounds for medicines and wellness products.
personas
- title: Biotech discovery or medicinal chemistry leaderpains:
- Obtain sufficient quantities of scarce natural molecules for research
- Screen and refine candidate molecules against a new therapeutic target
- title: Head of ingredient sourcing at a wellness brandpains:
- Secure reproducible supply of high-value ingredients that are difficult to extract from plants
- Assess purity, scale and commercial viability before product development
- title: Bioprocess development directorpains:
- Move an engineered strain from lab experiments toward pilot scale
- Coordinate fermentation and downstream analysis while controlling variability
icp
- text: Biotech and pharmaceutical research teams investigating peptides, alkaloids, cannabinoids or other scarce natural molecules.
- text: Wellness and supplement product developers looking for ingredients produced through microbial fermentation.
- text: Research and commercial partners with a defined molecule or target and resources to evaluate technical feasibility and supply requirements; company size is not publicly specified.
message pillars
- text: Combine biological engineering with computational design.
- text: Use fermentation to make natural products available reproducibly.
- text: Connect molecule design to testing and pilot-scale infrastructure.
objections
- objection: Can fermentation produce our target at the required purity and yield?response: Ask for compound-specific analytical data, strain feasibility and a defined pilot before making a supply commitment.
- objection: AI-generated candidates may not translate into usable molecules.response: Discuss the wet-lab testing and analytical feedback loop, and evaluate results for the particular target.
- objection: Can this meet our clinical or commercial regulatory requirements?response: Request documentation and qualification for the intended use; the website does not establish approval for every compound.
competitors
- name: Ginkgo Bioworkswhy: Offers organism engineering and biomanufacturing development services.
- name: Brightseedwhy: Uses computational discovery for bioactive compounds and health ingredients.
influencers
- name: Jacob Voganurl: https://www.syntheticbiologysummit.com/2025/event-speaker/jacob-voganwhy: Co-founder and scientific leader speaking publicly on synthetic biology and therapeutic compounds.
keywords
- precision fermentation natural ingredients
- biosynthetic cannabinoid production
- fermentation derived natural compounds
- synthetic biology ingredient development
- AI peptide discovery
- microbial strain engineering
voice
- scientific
- optimistic
- explanatory
signals
- text: A drug discovery program seeks a reliable source of a scarce plant-derived research compound.
- text: A wellness ingredient company explores fermentation or launches a new natural compound program.
stack
- engineered yeast
- LC-MS
- HPLC
- GC
pricing
model: unknown
motion
sales_ledchannels
- website
- scientific conferences
confidence
mediumFounders
- name: Sher Butttitle: Founder/CEOrole: CEO
- name: Jacob Vogantitle: Founderrole: Founderbio: Co-founded CB Therapeutics to create new biological supply chains for rare natural products that can help treat disease, increase healthspan, and promote longevity.